A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma
Status:
Completed
Trial end date:
2020-08-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of cabozantinib measured by Independent
Radiology Committee (IRC)-assessed objective response rate (ORR) in Japanese participants
with advanced renal cell carcinoma (RCC) that has progressed after prior vascular endothelial
growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) therapy.